Related Experiment Videos
Recent advances in gestational trophoblastic disease
E S Newlands1, F J Paradinas, R A Fisher
1Department of Cancer Medicine, Imperial College, Charing Cross Hospital, London, United Kingdom.
Hematology/Oncology Clinics of North America
|March 18, 1999
Summary
Gestational trophoblastic disease (GTD) management has improved due to recent advances. Treatment involves chemotherapy for persistent GTD and surgery or cisplatin for relapsing cases, preserving fertility.
Area of Science:
- Gynecology
- Oncology
- Reproductive Medicine
Background:
- Significant advancements in understanding gestational trophoblastic disease (GTD) over the past two decades.
- Improved diagnostic capabilities and management strategies for GTD have enhanced patient outcomes.
- GTD requires specialized follow-up and treatment protocols.
Purpose of the Study:
- To summarize the current understanding and management of gestational trophoblastic disease.
- To outline recommended treatment pathways for low-risk and high-risk GTD.
- To highlight effective strategies for managing relapsing or resistant GTD.
Main Methods:
- Review of recent advances in GTD diagnosis and management.
- Description of chemotherapy regimens: methotrexate and folinic acid for low-risk disease.
- Explanation of EMACO (etoposide, actinomycin-D, methotrexate, vincristine, cyclophosphamide) for high-risk disease and EP/EMA combinations for resistant cases.
Main Results:
- Improved diagnosis and prognosis for patients with GTD.
- Effective chemotherapy regimens (methotrexate, EMACO) for persistent disease, preserving fertility.
- Successful treatment of relapsing/resistant GTD with surgery and/or cisplatin-based chemotherapy (EP/EMA).
Conclusions:
- Current management strategies have significantly improved outcomes for GTD patients.
- Specialized centers and tailored chemotherapy regimens are crucial for effective GTD treatment.
- Fertility-sparing treatment options are available for most GTD cases, including relapsing or resistant disease.